High-sensitivity drug screening platform based on piggyBac transposition system and application of high-sensitivity drug screening platform

Through a highly sensitive drug screening platform based on piggyBac transposition system, the problems of mutagen hazard, insufficient gene knockout coverage and multidrug resistance in drug screening in the prior art are solved, and chemical small molecule drug targets are realized The efficient identification and drug screening of points have promoted the accuracy and personalization of drug research and development.

CN118932033APending Publication Date: 2024-11-12CHINA PHARM UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411143965.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art has problems such as mutagen hazard, insufficient knockout coverage, and insensitivity to drug treatment in drug screening, which limits the accuracy and personalized discovery of chemical small molecule drug targets.

Method used

Using a highly sensitive drug screening platform based on piggyBac transposal system, super-sensitive strains and strains containing inducible PB transposon mutagenesis system were obtained through multiple rounds of hybridization to construct PB-MDR strains, and the entire genome was achieved using the PB transposon system. Range of efficient random mutations and high-throughput sequencing reduces multidrug resistance and improves drug sensitivity.

Benefits of technology

It significantly improves the sensitivity of drug screening, shortens the screening cycle, reduces costs, and achieves efficient identification of the potential targets and antagonistic mechanism of the ferrodysfunction inducer Erastin, promoting precise and personalized drug research and development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932033A_ABST
    Figure CN118932033A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of medicines, and discloses a high-sensitivity medicine screening platform based on a piggyBac transposition system and application thereof. A super sensitive strain and a strain containing an inducible PB transposon mutagenesis system are subjected to multiple rounds of hybridization to finally obtain a PB-MDR strain containing a PB transposon, and the PB-MDR strain containing the PB transposon can be used for exploring a drug action target and a cell antagonism mechanism; through a gene knockout technology, multiple drug resistance is inhibited, and the drug action sensitivity is improved; the piggyBac transposon can be used for realizing efficient random mutation in a whole genome range; by utilizing a next-generation sequencing technology, whole-genome high-throughput PB mutagenesis site identification is realized, and a whole-genome pharmacodynamic regulation network is constructed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of medicine, and in particular to a highly sensitive drug screening platform based on the piggyBac transposition system and its application in high-throughput chemical small molecule drug screening. Background Art

[0002] In the past 20 years, drug development has made significant progress and breakthroughs. Researchers use advanced technologies and innovative methods to continuously discover and develop new drugs. By deeply understanding the biological mechanisms of diseases and drug targets, more precise and effective treatments can be designed. The application of high-throughput screening technology has accelerated the drug discovery process, allowing researchers to evaluate the effectiveness and safety of candidate drugs more quickly. The development of bioinformatics and computational chemistry has provided researchers with powerful tools to reveal the interactions between drugs and biomolecules and optimize drug design. Despite the great progress made in drug development, there are still many challenges in further confirming drug targets.

[0003] Confirming the physiological target and specificity of a drug is a crucial and challenging part of the drug development process. Biological systems are inherently complex, including different types of interconnected cells, tissues, and organs. There are a large number of potential targets in organisms, and the target specificity of a drug determines its effectiveness and safety in treating diseases. If a drug lacks specificity, it may cause serious side effects or toxic reactions. Determining the target specificity of a drug requires a large number of in vitro and in vivo experiments to evaluate the selective effects of drug molecules on different targets and the effects on non-target targets. Therefore, the further development and application of many chemical small molecules and drug candidates are limited.

[0004] Chemical genetics is an interdisciplinary subject that integrates the principles of chemistry and genetics. It aims to use chemical methods to study and control the transmission and expression of genetic information in organisms. Chemical genetics also provides new ideas for the design and development of new drugs. It uses chemical small molecules to intervene in biological systems, and uses selective small molecules to quickly, reversibly and conditionally interfere with the function of proteins in biological systems to find small molecule targets and antagonistic mechanisms in the body. Chemical methods are used to study and discover intracellular signal transduction pathways and new drug targets.

[0005] Schizosaccharomyces pombe, also known as fission yeast, has become a widely used model organism for genetic research due to its relatively simple genome structure, easy operation, and highly conserved gene function. More and more chemical genetics studies and methods use the fission yeast model for drug screening. As one of the ideal models for chemical genetics drug screening, fission yeast has achieved results in studying the targets and cell antagonism mechanisms of chemical small molecule drugs. First, fission yeast can be used as a high-throughput platform model for drug screening. Using automation technology and high-throughput analysis methods, a large number of compounds can be quickly evaluated to find compounds with specific biological activities. Second, many chemical mutagens such as alkylating agents and azides, as well as physical mutagens including electromagnetic radiation, can randomly mutate the yeast genome and screen for gene mutations related to drug action. Third, the fission yeast genome knockout library is also one of the common methods for drug screening, which can identify drug targets and explore knockout mechanisms through experiments. At present, the existing technical means of fission yeast have certain limitations, which restricts its application in drug screening. First, mutagens are harmful to operators, and the resulting mutations are difficult to detect. Secondly, the construction of gene knockout libraries is based on people's understanding of the genome at a specific time, and can only cover most of the coding regions of the genome (non-essential genes), and is not suitable for the screening of functionally important essential genes and non-coding regulatory elements with unknown information. In addition, the multi-drug resistance (MDR) of fission yeast makes the yeast system insensitive to most drug treatments, and requires large doses to increase drug concentrations. Therefore, there is an urgent need to develop a platform with short cycle, low cost, and wide gene screening coverage to adapt to the increasingly precise and personalized small molecule drug target discovery and new drug exploration. Summary of the invention

[0006] The purpose of the present invention is to solve the deficiencies in the prior art and provide a highly sensitive drug screening platform based on the piggyBac (PB) transposition system and its application; a fission yeast strain that is super sensitive to drugs and a strain containing an inducible PB transposon mutagenesis system are subjected to multiple rounds of hybridization to finally obtain yeast strains with PB transposons and different drug sensitivities, and establish a high-throughput chemical small molecule drug screening platform. This drug screening platform is then used to screen a variety of chemical small molecule drugs.

[0007] In order to achieve the above object, the present invention is achieved through the following technical solutions:

[0008] In a first aspect, the present invention provides a highly sensitive drug screening platform based on the piggyBac transposition system, wherein the screening platform is obtained by performing multiple rounds of hybridization between a super-sensitive strain and a strain containing an inducible PB transposon mutagenesis system, and finally obtaining a PB-MDR strain containing a PB transposon, i.e., obtaining a screening platform;

[0009] The super sensitive strain is a fission yeast strain with knockout genes of bfr1, pmd1, mfs1, caf5, pap1, dnf2 and erg5, the super sensitive strain is SD405 or SD406, the genotypes of SD405 and SD406 are leu1-ade6-mat1Δ::hphSEVM caf5Δ::bsdMX pap1Δpmd1Δmfs1Δbfr1Δdnf2Δerg5Δ::ura4, and the mating types are h+ and h- respectively;

[0010] The strain containing the inducible PB transposon mutagenesis system is SD134, whose genotype is ura4D-18his3-D1arg6::PB[ura4+]leu1-32::pDUAL-PBase(leu1+), and mating type is h-;

[0011] In order to obtain PB-MDR strains containing PB transposons and having different sensitivities to the same drugs, wild-type strains were used in the hybridization process to obtain a mating type opposite to that of the existing PB-MDR strains, which was convenient for the next round of hybridization; the wild-type strain was SD114, whose genotype was leu1-32 ura4-D18 ade6-M210his3-D1 and mating type was h+.

[0012] The PB-MDR strain containing the PB transposon is SD1260, SD1262, SD1264, SD1266, SD1436, SD1437, SD1438, SD1463, SD1832 or SD1833;

[0013] The genotype of SD1260 is leu1-ade6-his3-D1 mat1Δ::hphSEVM caf5Δ::bsdMXmfs1Δbfr1Δdnf2Δarg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-;

[0014] The genotype of SD1262 is leu1-ade6-his3-D1 mat1Δ::hphSEVM caf5Δ::bsdMXmfs1Δbfr1Δarg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-;

[0015] The genotype of SD1264 is leu1-ade6-his-D1 mat1Δ::hphSEVM pmd1Δpap1Δbfr1Δarg6::PB[ura4]leu1-32::pDUAL-pBase(leu1+), and the mating type is h-;

[0016] The genotype of SD1266 is leu1-ade6-his-D1 mat1Δ::hphSEVM pap1Δmfs1Δbfr1Δerg5::ura4 arg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-;

[0017] The genotype of SD1436 is leu1-ade6-mat1Δ::hphSEVM caf5Δ::bsdMX pap1Δpmd1Δmfs1Δbfr1Δarg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-;

[0018] The genotype of SD1437 is leu1-ade6-mat1Δ::hphSEVM erg5::ura4 pap1Δpmd1Δmfs1Δbfr1ΔΔarg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h+;

[0019] The genotype of SD1438 is leu1-ade6-mat1Δ::hphSEVM erg5::ura4 pap1Δpmd1Δmfs1Δbfr1ΔΔarg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-;

[0020] The genotype of SD1463 is leu1-ade6-mat1Δ::hphSEVM caf5::bsdMX pap1Δpmd1Δmfs1Δbfr1Δerg5::ura4 arg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h+;

[0021] The genotype of SD1832 is leu1-ade6-mat1Δ::hphSEVM caf5::bsdMX pap1Δpmd1Δmfs1Δbfr1Δdnf2Δerg5::ura4 arg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h+;

[0022] The genotype of SD1833 is leu1-ade6-mat1Δ::hphSEVM caf5::bsdMX pap1Δpmd1Δmfs1Δbfr1Δdnf2Δerg5::ura4 arg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-.

[0023] In a second aspect, the present invention provides the application of a high-sensitivity drug screening platform based on the piggyBac transposition system in chemical small molecule drug screening.

[0024] Specifically, a highly sensitive drug screening platform based on the piggyBac transposition system is provided for the application in the screening of potential targets of the ferroptosis inducer Erastin and the ferroptosis antagonism mechanism.

[0025] The specific application steps are as follows:

[0026] Step 1, obtain a suitable PB-MDR strain and a suitable Erastin treatment concentration through a spot selection experiment, and then obtain a suitable Erastin treatment time through a growth curve experiment; specifically: use a spot selection experiment to conduct a drug sensitivity test on the strain, and by comparing it with the wild-type yeast phenotype, the strain treated with the drug will be lethal, proving that the strain of this screening platform is sensitive to chemical small molecules, and find a suitable drug treatment concentration from it, that is, at this concentration, the super-sensitive strain shows sensitivity to Erastin but is not lethal. Then find a suitable Erastin treatment time through a growth curve experiment.

[0027] Step 2, construct a super-sensitive mutant library with PB insertion in the whole genome, and then use the spot selection experiment to obtain the Erastin drug treatment concentration and time to treat the super-sensitive mutant library with PB insertion, and then collect the bacteria and extract the genome; specifically: induce PB transposon transposition, the strain used is SD1260, calculate the transposition efficiency, and prove that this screening platform can construct a super-sensitive mutant library with PB insertion in the whole genome after induction. Then the PB mutant library strain is treated with Erastin drugs. According to the results of the spot selection experiment, the PB mutant library strain can be treated with 0μM, 10μM and 30μM Erastin. The appropriate time for treating the PB mutant library through the growth curve experiment is the time required for the strain to grow for 5-6 generations, and then the bacteria are collected and the genome is extracted.

[0028] Step 3, the super-sensitive mutant library of PB inserted after Erastin treatment in step 2 was constructed by Tn5 transposase method, and then high-throughput sequencing was performed; specifically: Tn5 transposase method library construction, the library construction samples are PB mutant library strains treated with 0μM, 10μM and 30μM Erastin; the library construction process includes sample genome fragmentation and addition of sequencing adapters, amplification of PB-specific fragments, enrichment of PB-specific fragments, and concentration measurement after enrichment of PB-specific fragments. High-throughput sequencing was used to detect the insertion site of TTAA of PB transposon in the fission yeast genome.

[0029] Step 4, bioinformatics analysis of Erastin's potential targets and cell antagonism mechanisms; specifically: bioinformatics analysis of Erastin's potential targets and cell antagonism mechanisms. Comparative analysis of the control group without Erastin treatment and the experimental group treated with Erastin can reveal sensitive and antagonistic gene mutations, and cluster analysis of the two types of genes can be performed to infer how unknown genes regulate cell ferroptosis, and at the same time construct a genome-wide regulatory network that responds to ferroptosis inducers.

[0030] The present invention has the following beneficial effects:

[0031] (1) The piggyBac transposon (PB transposon)-based biological mutagenesis method is used: it is a type of mobile DNA fragment widely present in the genome, called transposable elements, also known as transposons. The transposon is excised from one location on the genome and then inserted into another location on the genome, that is, it is transposed through a "cut-and-paste" mechanism, thereby achieving random mutations in the genome. The PB transposon used in this screening platform is one of the most widely used transposon systems. The PB transposon is 2475 bp long, with 13 bp of terminal inverted repeat sequences, 19 bp of secondary terminal inverted repeat sequences and a transposase containing 594 amino acids at both ends. Studies have shown that the PB transposon specifically recognizes the TTAA site on the genome and inserts. When the PB transposon sequence is excised from the genome, the double-strand breaks left behind are basically accurately repaired, so it is easy to verify whether the insertion of the transposon causes the phenotype by analyzing the phenotype after excision. In addition, compared with other transposons, PB transposons have a lower tendency to local jumps, and the chromosomal distribution preference of PB insertion sites is not obvious. Therefore, limited local jumps have little effect on mutagenesis. The fission yeast genome contains about 130,000 TTAA insertion sites, covering about 95% of protein-coding genes. The genome mutagenesis system based on PB transposons has been used in fission yeast, which has significant advantages such as high transposition efficiency, high accuracy, and easy detection, and can induce mutations throughout the genome.

[0032] (2) The efficient drug screening platform constructed by the present invention, that is, the PB transposon random mutagenesis system (referred to as PB-MDR strain) is introduced into the super-sensitive strain, in order to screen and identify the targets or cell antagonistic mechanisms of important medicinal chemical small molecules, and promote clinical drug development. In order to verify the practicality of this screening platform, we selected ferroptosis inducers to carry out experiments. Ferroptosis is an iron-dependent, non-apoptotic form of cell death characterized by the accumulation of lipid reactive oxygen species (ROS). Its mechanism of occurrence has been partially revealed: first, overloaded iron ions produce a large number of hydroxyl free radicals through the Fenton reaction, thereby catalyzing a series of oxidative stress reactions, causing damage to the cell nucleus, cell membrane, organelles, proteins, etc.; second, the lipid metabolism pathway ultimately leads to ferroptosis by inducing lipid peroxidation; third, a large amount of antioxidant GSH is consumed by lipid peroxides and hydroperoxides, resulting in the inactivation of GPX4. Erastin is a classic ferroptosis inducer that inhibits the cystine-glutamate antiporter, preventing extracellular cystine from entering the cell, blocking the synthesis of intracellular glutathione, weakening the cell's antioxidant capacity, and ultimately leading to ferroptosis. Ferroptosis plays an important regulatory role in the occurrence and development of a variety of diseases such as tumors, nervous system diseases, acute kidney injury, and ischemia-reperfusion. By regulating the ferroptosis pathway, it is expected to provide effective therapeutic strategies for a variety of diseases. Therefore, finding potential physiological targets and antagonistic mechanisms of ferroptosis is of great significance for cancer treatment and neurodegenerative diseases. Therefore, we used this drug screening platform to screen the ferroptosis inducer Erastin, constructed a PB transposon mutation library, and compared the relative abundance of different PB insertions between drug treatment and control groups by high-throughput sequencing, revealing the unknown targets of Erastin and the antagonistic mechanism of cells in response to ferroptosis. At the same time, this result was used to prove the efficiency and reliability of this chemical genetics screening platform.

[0033] (3) The present invention provides a high-sensitivity drug screening method based on the PB transposon system. The advantages of this technology are: ① The PB transposon system can achieve efficient random mutations across the entire genome; ② Gene knockout technology can be used to inhibit multidrug resistance and improve drug sensitivity; ③ Second-generation sequencing technology can be used to achieve high-throughput PB mutagenesis site identification across the entire genome and construct a genome-wide pharmacodynamic regulation network. This platform significantly improves the sensitivity of drug screening. The detection sensitivity of the tested drugs is generally improved by 3-6 orders of magnitude (10 3 -10 6 ), lowering the screening "threshold"; the experimental cycle is 2-3 weeks, which greatly shortens the drug screening and target identification cycle; the screening cost is RMB 500 per small molecule, which reduces the screening cost several times; no professional drug screening equipment is required, which effectively promotes the precise and personalized clinical drug development. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 is a flow chart of building a chemical genetics screening platform in Example 1;

[0035] Figure 2 is a diagram showing the working principle of the PB transposon in Example 1;

[0036] Figure 3 This is a result diagram of the point selection experiment in Example 2 verifying that the PB-MDR strain has sensitivity under Erastin treatment;

[0037] Figure 4 is a flow chart of PB transposon library construction in Example 3;

[0038] Figure 5 is a map of TTAA insertion sites analyzed from the high-throughput sequencing results in Example 3;

[0039] Figure 6 The normalized sample M value distribution and MA graph are analyzed from the high-throughput sequencing results in Example 3;

[0040] Figure 7 The chromosome coordinate map of the gene with abnormal values ​​of the sample analyzed by high-throughput sequencing results in Example 3;

[0041] Figure 8 This is a graph showing a stronger sensitivity result after the outlier gene is knocked out under Erastin treatment in Example 4. DETAILED DESCRIPTION

[0042] The present invention is further described by way of the following examples, which do not limit the present invention in any way. Without departing from the technical solution of the present invention, any modification or change made to the present invention that is easily implemented by a person of ordinary skill in the art will fall within the scope of the claims of the present invention.

[0043] Example 1 Construction of a chemical genetics screening platform (PB-MDR strain)

[0044] 1. Materials

[0045] The strains used in the present invention can all be purchased from commercial sources. The strains used in the examples are all from the Beijing Institute of Life Sciences. SD405 (Schizosaccharomyces pombe) and SD406 (Schizosaccharomyces pombe) are obtained by knocking out the bfr1, pmd1, mfs1, caf5, pap1, dnf2, and erg5 genes of Schizosaccharomyces pombe by transformation and homologous recombination technology. SD134 (Schizosaccharomyces pombe) is obtained by transforming and inserting the PB transposon into the fission yeast by homologous recombination technology. SD114 (Schizosaccharomyces pombe) is a wild-type strain. The DNA sequences and amino acid sequences of all genes can be found at www.pombase.org. The genotypes of the fission yeast strains and the super-sensitive strains are as follows:

[0046] Table 1. Fission yeast strains and super sensitive strain genes

[0047]

[0048] The primers for identifying caf5, pap1, pmd1, mfs1, bfr1, dnf2, erg5, PB, and PBase are as follows:

[0049] Table 2 PCR identification primers

[0050]

[0051]

[0052] 2000× Thiamine (Vitamin B1) stock solution: Weigh 2 g of thiamine, dilute to 0.2 L with distilled water, filter and sterilize, and store at 4°C away from light.

[0053] 50× salt stock solution: weigh 52.5 g magnesium chloride hexahydrate, 0.556 g anhydrous calcium chloride, 50 g anhydrous potassium chloride, 2 g anhydrous sodium sulfate, and dilute to 1 L with distilled water.

[0054] 10000× mineral stock solution: weigh 5 g boric acid, 4.0 g manganese sulfate monohydrate, 4 g zinc sulfate heptahydrate, 2 g ferric chloride hexahydrate, 0.4 g molybdic acid, 1 g potassium iodide, 0.4 g anhydrous copper sulfate, and 10 g citric acid monohydrate, and dilute to 1 L with distilled water.

[0055] 1000× vitamin stock solution: weigh 0.5 g ubiquitin, 5 g niacin, 5 g inositol, and 5 mg biotin, and dilute to 0.5 L with distilled water.

[0056] 50× nutrient supplement stock solution: weigh 12.5 g leucine, 3.75 g uracil, 3.75 g adenine, 10 g histidine, and dilute to 0.5 L with distilled water.

[0057] Fission yeast YEA medium: 4.5g yeast extract, 27g anhydrous glucose, 0.09g adenine, fully dissolved on a magnetic stirrer, then dilute to 0.9L with distilled water, put into a 1L blue-capped bottle, stick a sterilization indicator tape on the bottle cap, and sterilize at 121℃ for 15 minutes. If you are preparing a solid culture medium, you need to add an additional 18g of agar.

[0058] PMG medium for fission yeast: 2.7g potassium hydrogen phthalate, 3.38g sodium glutamate, 5.0g disodium hydrogen phosphate dodecahydrate, 18g glucose, 18mL 50× salt stock solution, 0.9mL 1000× vitamin stock solution, 0.09mL 10000× mineral stock solution, if histidine (H) is needed: 0.203g, if adenine (A) is needed: 0.203g, if arginine (R) is needed: 0.203g. Dissolve fully on a magnetic stirrer, then dilute to 0.9L with distilled water, put into a 1L blue-capped bottle, stick a sterilization indicator tape on the bottle cap, and sterilize at 121℃ for 15 minutes. If solid culture medium is to be prepared, 18g of agar needs to be added. As needed, after sterilization is completed and the bottle is cooled to a temperature that is not too hot to touch, add 0.45 mL of 2000× ammonium sulfate stock solution and continue stirring for five minutes before inverting the plate.

[0059] Fission yeast SPAST medium: 9g glucose, 0.9g anhydrous potassium dihydrogen phosphate, 0.9mL 1000× vitamin stock solution, 4.05mL 50× nutritional supplement, if necessary, add arginine (R): 0.041g, if necessary, add lysine (K): 0.041g. Dissolve fully on a magnetic stirrer, then dilute to 0.9L with distilled water, put into a 1L blue-capped bottle, stick a sterilization indicator tape on the bottle cap, and sterilize at 121℃ for 15 minutes. If you are preparing a solid culture medium, you need to add an additional 18g of agar. After sterilization, add 0.45mL of 2000× ammonium sulfate stock solution when the bottle is not hot to the touch, continue stirring for five minutes, and pour it into a plate.

[0060] 2. Methods

[0061] 2.1 Hybridization of strains SD405 and SD134 (SD405×SD134)

[0062] SD405 and SD134 were streaked onto YEA solid plates from a -80°C refrigerator and placed in a 30°C incubator for 36 hours. Fresh bacteria were scraped from the YEA solid plates, the two bacteria were mixed at a ratio of 1:1, resuspended in 30 μL of sterile water, and spotted on SPAST solid plates, and incubated at 30°C for 24 hours. After 24 hours, the spore production effect of the colonies on the SPAST solid plates was observed under an optical microscope and recorded. If the spore production effect was good, the bacteria on the SPAST solid plates were scraped and digested with snail enzyme overnight to release the spores. The digested spore stock solution was washed twice with sterile water, diluted 1000 times and 10000 times, spores were spread on PMGHRAT solid plate, and then transferred to PMGHAT solid plate, clones with short PMGHAT and long PMGHRAT were selected, and the strain was lysed with 10 μL of 0.02M sodium hydroxide at 95°C for 10 minutes, and 1 μL was taken as the template of PCR reaction system after mixing, and PCR identification was performed on caf5, pap1, pmd1, mfs1, bfr1, dnf2, erg5, PB, and Pbase respectively using the PCR identification primers in Table 2. The PCR reaction system is as follows:

[0063] Table 3 PCR reaction system

[0064]

[0065] Mix the above components evenly and follow the following procedure:

[0066] (1) Pre-denaturation: 95°C, 3 min

[0067] (2) Denaturation: 95°C, 10 sec

[0068] (3) Annealing: 55°C, 30 seconds

[0069] (4) Extension: 72°C, time depends on the length of the amplified fragment (1 kb min)

[0070] (5) Repeat steps (2) to (4) 30 times

[0071] (6) 12℃ insulation

[0072] According to the PCR identification results, PB-MDR strains with different drug susceptibility were obtained, and the genotypes were as follows:

[0073] Table 4 Genotypes of PB-MDR strains

[0074]

[0075] 2.2 SD114 was hybridized with SD134 to obtain a strain with the same genotype as SD134 but opposite mating type, namely SD1206.

[0076] 2.3 SD1206 was hybridized with SD1264 to obtain a strain with the same genotype as SD1264 but opposite mating type, namely SD1381.

[0077] 2.4 SD1381 was hybridized with SD1260 and SD1266 to obtain PB-MDR strains with different drug sensitivities. The genotypes are as follows:

[0078] Table 5 Genotypes of PB-MDR strains

[0079]

[0080]

[0081] 2.5 SD1436 was hybridized with SD1438 to obtain PB-MDR strains with the following genotypes:

[0082] Table 6 Genotypes of PB-MDR strains

[0083]

[0084] 2.6 SD406 was hybridized with SD1463 to obtain PB-MDR strains with the following genotypes:

[0085] Table 7 Genotypes of PB-MDR strains

[0086]

[0087] The construction process of PB-MDR strains is as follows Figure 3 As shown. After the PB-MDR strain is constructed, when using this screening platform, it is necessary to prove that the PB-MDR strain is sensitive to the drug used (the drug used in this embodiment is an ferroptosis inducer (Erastin), that is, a suitable PB-MDR strain and a suitable drug treatment concentration are found through a point selection experiment, and a suitable drug treatment time is found; then the PB-MDR strain is induced to transpose, and a hypersensitive mutant library of PB insertions in the entire genome is constructed, and this hypersensitive mutant library is treated at 10 and 30 μM Erastin concentrations for 5-6 generations, and the strains are collected. The specific implementation process is shown in Example 2.

[0088] Example 2 Erastin drug screening process

[0089] 1. Materials

[0090] Erastin: 25 mg was dissolved in 4.57 mL of dimethyl sulfoxide to prepare a 10 mM stock solution, filtered, dispensed into 200 μL tubes, and stored in a -20°C refrigerator.

[0091] Fission yeast YEA Erastin medium: After the YEA medium is sterilized at 121℃ for 15 minutes, when the bottle is no longer hot, add 10mM stock solution to prepare working solution concentrations of 10μM, 30μM, and 100μM YEA Erastin plates.

[0092] 2. Methods

[0093] 2.1 Point selection experiment verifies that PB-MDR strains are sensitive to Erastin treatment

[0094] Streak SD1260, SD1463 and the wild-type strain (SD114) from the -80℃ freezer onto a YEA solid plate and place in a 30℃ incubator for 36 hours. Use 3mL YEA liquid culture medium to shake the bacteria the night before and dilute to OD600=0.3 the next morning. When they grow to the logarithmic growth phase with OD600=0.6-0.8, take 0.4OD of each of the three strains and dilute them into 1mL YEA liquid culture medium. Dilute three times in sequence on a 96-well plate, 5 times each time, and use an eight-row pipette to draw the bacterial solution and spot it on YEA and YEA10 / 30 / 100 / μM Erastin solid plates. Place in a 30℃ incubator for culture and observe its growth trend every day. The results are as follows Figure 3 As shown, the wild-type strain showed no sensitivity to Erastin, while the SD1260 and SD1463 strains showed increasing sensitivity as the concentration of Erastin treatment increased, demonstrating that this PB-MDR strain can be used for subsequent screening of Erastin.

[0095] Next, we need to use the growth curve to find the appropriate Erastin treatment time so that the drug-treated group strains and the non-drug-treated group strains show growth differences. Based on the point-selection experimental results, it was decided to select the SD1260 hypersensitive strain for subsequent experiments, and the Erastin treatment concentrations were selected as 10 and 30 μM.

[0096] 2.2 Plotting the 24-hour growth curves of the hypersensitive strain (SD1260) and the wild-type strain (SD114) in the control group under 10 and 30 μM Erastin treatment

[0097] SD1260 and SD114 were streaked onto YEA plates from a -80℃ refrigerator and placed in a 30℃ incubator for 36h. SD1260 and SD114 were revived in YEA liquid medium the night before and diluted to 5mL YEA liquid medium the next morning to an OD600 of 0.15. No drugs were added to SD1260 and SD114 in the control group, while Erastin was added to SD1260 and SD114 in the experimental group at a final concentration of 10μM and 30μM. The OD600 value of the bacterial solution was measured within 3, 6, 9, 12, and 24 hours after drug treatment. The growth curve showed that SD1260 and SD114 showed growth differences when the two strains grew for 4 generations under 10 and 30μM Erastin treatment. In order to make the difference more obvious, the time required for the strain to grow for 5-6 generations was determined to be the appropriate Erastin treatment time.

[0098] Next, we need to use strain SD1260 to induce transposition of the PB transposon. The principle of transposition is as follows Figure 2 As shown, strain SD1260 was transposed at PMGHAR and inserted into the TTAA site, causing gene mutation. This method covered about 95% of protein-coding genes and constructed a genome-wide hypersensitive mutant library of PB insertion.

[0099] 2.3 Inducing PB transposon transposition and constructing a genome-wide hypersensitive mutant library of PB insertion

[0100] SD1260 was streaked onto a YEA plate from a -80°C freezer and placed in a 30°C incubator for 36 hours. SD1260 was revived in YEA liquid medium the night before, and the bacteria were harvested the next morning, washed three times, and then diluted into PMGHAR liquid medium to induce PB transposition for 60 hours. After the transposition is completed, the induced bacteria were spread on ten PMG-HAT plates, 0.5OD per plate, to screen the strains that have completed the transposition; at the same time, the induced bacteria were spread on PMG-RHAT at 0.0001OD and 0.00001OD, and on PMG-HAT at 0.1 0.01 0.001OD, and the transposition efficiency was calculated. After five days, a layer of strains was observed on the PMG-HAT plates. Cells on ten PMGHAT plates were scraped with a cell scraper and collected into 50 mL YEA liquid culture medium. Then 50 OD of bacteria were diluted into a conical flask containing 100 mL YEA liquid culture medium to an OD600 of 0.5. The cells were cultured at 30°C and 220 rpm for 4-5 hours to restore their vitality.

[0101] Next, the rejuvenated hypersensitive mutant library needs to be treated for 5-6 generations without drug treatment, 10μM and 30μM Erastin concentrations. The purpose is to obtain which genes respond to Erastin treatment, whether the gene is upregulated or downregulated compared with the control group, and to explore the function of the gene.

[0102] 2.4 Treat this hypersensitive mutant library at 10 μM and 30 μM Erastin concentrations for 5-6 generations

[0103] The strains with restored vitality were diluted into two conical flasks containing 100mL of YEA liquid medium, one of which was a control group without drug addition, and the experimental group was treated with 10μM and 30μM Erastin, respectively, and cultured at 30℃ shaker, 220rpm, with an initial OD600=0.1. When OD600=1.6, it was diluted again to OD600=0.4. Erastin was still added to the experimental group, and the bacteria were shaken to OD600 of 1 (a total of 5 to 6 generations), with a total of 100 OD samples. When collecting bacteria, they were washed twice with sterile water, and each sample was divided into three portions and placed in a 1.5mL EP tube, and after liquid nitrogen quick freezing, they were frozen at -80℃. A portion of the control group sample without drug treatment and the experimental group sample treated with 10μM and 30μM Erastin were taken out for Tn5 transposase library construction, and samples directly used for high-throughput sequencing were obtained.

[0104] Example 3 Tn5 transposase library construction

[0105] 1. Materials

[0106] 50×TE: weigh 60.57g Tris and 14.6g EDTA, adjust the pH to 8.0 with hydrochloric acid, dilute to 1L with distilled water, and dilute to 1×TE before use.

[0107] 3M sodium acetate: weigh 2.46g sodium acetate and dilute to 10mL with distilled water

[0108] 2. Methods

[0109] 2.1 Extraction of sample genome

[0110] In the above experimental operation, samples from the control group and the drug treatment group were collected. These samples will be used for library construction and sequencing. First, the genome of these samples must be extracted.

[0111] (1) Take out the sample from the -80℃ freezer and thaw it. Add 100μL 1×TE to the 1.5mL EP tube used to collect the bacteria and resuspend the cells. Transfer the tube to the threaded tube and add 0.5mm glass beads to the tube. Use a homogenizer to break the cells. The program is 4000rpm, 30S each time, 45S interval, and continue for three cycles.

[0112] (2) Add 200 μL 1×TE to the threaded tube after centrifugation, and use a needle (red-hot) to poke two holes at the bottom of the tube. Put the threaded tube into a 1.5 mL EP tube and centrifuge at 3000 rpm for 1 min. At this time, the TE solution containing the genome is centrifuged into the 1.5 mL EP tube.

[0113] (3) Add 300 μL of DNA extraction reagent (phenol chloroform = 1:1) to a 1.5 mL EP tube, mix well, centrifuge (12000 rpm, 5 min), transfer the supernatant to a new tube, and repeat once. Add 300 μL of chloroform, mix well, centrifuge (12000 rpm, 5 min), and transfer the supernatant to a new tube.

[0114] (4) Add 28 μL of 3 M sodium acetate solution and then add 210 μL of isopropanol. Observe that the solution becomes turbid and centrifuge (12000 rpm, 30 min, 4°C) to obtain a white precipitate at the bottom.

[0115] (5) Discard the solution, retain the particles, add 500 μL of 70% ethanol, and centrifuge (13000 rpm, 2 min). Discard the supernatant, centrifuge quickly, and discard the residual solution. Open the container, wait for the ethanol to dry, and add 200 μL of 1×TE buffer to completely dissolve the particles.

[0116] (6) Add 1 μL RNase (10 mg / mL), mix well, and incubate at 37°C for 30 minutes. Add 2 μL proteinase K (20 mg / mL), mix well, and incubate at 37°C for 30 minutes. Add 300 μL DNA extraction reagent, mix well, and centrifuge (12000 rpm, 5 minutes); transfer the supernatant to a new centrifuge tube.

[0117] (7) Add 20 μL of 3 M sodium acetate and 500 μL of 100% ethanol and place at -20°C for more than 2 h.

[0118] (8) Centrifuge the sample (12000 rpm, 30 min, 4°C), discard the supernatant, retain the DNA microspheres, add 500 μL of 70% ethanol for washing, and centrifuge (13000 rpm, 2 min). Discard the solution, centrifuge quickly, discard the residual solution, keep the EP tube open, and wait for the ethanol to dry.

[0119] (9) Add 50-200 μL 1× TE buffer to completely dissolve the genomic DNA.

[0120] (10) Use Qubit to measure the concentration of the genome and dilute a portion of the genomic DNA to 100 ng μL.

[0121] 2.2 Database Construction

[0122] This library was constructed using the TransNGS Tn5 DNA Library Prep Kit for Illumina, catalog number KP101-11. The i7 and i5 sequences used are as follows:

[0123]

[0124] The database construction process is as follows Figure 4 As shown, the library construction process includes sample genome fragmentation and addition of sequencing adapters, amplification of PB-specific fragments, enrichment of PB-specific fragments, and concentration measurement of enriched PB-specific fragments.

[0125] 2.3 High-throughput sequencing and bioinformatics analysis of Erastin targets and cell antagonism mechanisms

[0126] Sequencing results were analyzed as Figure 5 , 6 , as shown in Figure 7. Figure 5 A map of TTAA insertion sites after PB transposon transposition is shown, covering the entire fission yeast genome. Figure 6 The high-throughput sequencing results show the normalized sample M value distribution and MA diagram. Figure 7 The chromosome coordinates of the outlier genes are shown, with Erastin-sensitive mutant genes and antagonistic genes marked. The genes spo9 and mdm31 were selected for point selection experiments to analyze the reliability of the screening results.

[0127] Example 4: Point Selection Experiment Verification of the Reliability of Analysis Results

[0128] 1. Materials

[0129] Fission yeast YEA Erastin medium: After the YEA solid medium is sterilized at 121°C for 15 minutes, add 10mM Erastin stock solution when the bottle is no longer hot to the touch, and prepare working solution concentrations of 10μM and 30μM YEA Erastin plates.

[0130] 2. Methods

[0131] According to the results of high-throughput sequencing analysis, sensitive mutant genes after PB insertion were selected for point selection experiment verification. Two genes, spo9 and mdm31, were selected and knocked out in strain SD1260. Compared with the SD1260 strain, the knockout strains showed higher sensitivity to Erastin, proving that the chemical screening system is effective. Figure 8 shown.

[0132] The above shows and describes the basic principles, main features and advantages of the present invention. However, the above is only a specific embodiment of the present invention, and the technical features of the present invention are not limited thereto. Any other implementation methods derived by any technician in the field without departing from the technical solution of the present invention should be included in the patent scope of the present invention.

Claims

1. A highly sensitive drug screening platform based on the piggyBac transposition system, characterized in that: The screening platform is obtained by performing multiple rounds of hybridization between a super-sensitive strain and a strain containing an inducible PB transposon mutagenesis system, and finally obtaining a PB-MDR strain containing a PB transposon, that is, obtaining a screening platform; The super sensitive strain is a fission yeast strain with knockout genes of bfr1, pmd1, mfs1, caf5, pap1, dnf2 and erg5, the super sensitive strain is SD405 or SD406, the genotypes of SD405 and SD406 are leu1-ade6-mat1Δ::hphSEVM caf5Δ::bsdMX pap1Δpmd1Δmfs1Δbfr1Δdnf2Δerg5Δ::ura4, and the mating types are h+ and h- respectively; The strain containing the inducible PB transposon mutagenesis system is SD134, whose genotype is ura4D-18his3-D1arg6::PB[ura4+]leu1-32::pDUAL-PBase(leu1+), and mating type is h-; In order to obtain PB-MDR strains containing PB transposon and having different sensitivities to the same drug, the wild-type strain was used in the hybridization process. The wild-type strain was SD114, whose genotype was leu1-32 ura4-D18 ade6-M210 his3-D1 and mating type was h+.

2. The highly sensitive drug screening platform based on the piggyBac transposition system according to claim 1, characterized in that: The PB-MDR strain containing the PB transposon is SD1260, SD1262, SD1264, SD1266, SD1436, SD1437, SD1438, SD1463, SD1832 or SD1833; The genotype of SD1260 is leu1-ade6-his3-D1 mat1Δ::hphSEVM caf5Δ::bsdMX mfs1Δbfr1Δdnf2Δarg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-; The genotype of SD1262 is leu1-ade6-his3-D1 mat1Δ::hphSEVM caf5Δ::bsdMX mfs1Δbfr1Δarg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-; The genotype of SD1264 is leu1-ade6-his-D1 mat1Δ::hphSEVM pmd1Δpap1Δbfr1Δarg6::PB[ura4]leu1-32::pDUAL-pBase(leu1+), and the mating type is h-; The genotype of SD1266 is leu1-ade6-his-D1 mat1Δ::hphSEVM pap1Δmfs1Δbfr1Δerg5::ura4 arg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-; The genotype of SD1436 is leu1-ade6-mat1Δ::hphSEVM caf5Δ::bsdMX pap1Δpmd1Δmfs1Δbfr1Δarg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-; The genotype of SD1437 is leu1-ade6-mat1Δ::hphSEVM erg5::ura4 pap1Δpmd1Δmfs1Δbfr1ΔΔarg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h+; The genotype of SD1438 is leu1-ade6-mat1Δ::hphSEVM erg5::ura4 pap1Δpmd1Δmfs1Δbfr1ΔΔarg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-; The genotype of SD1463 is leu1-ade6-mat1Δ::hphSEVM caf5::bsdMX pap1Δpmd1Δmfs1Δbfr1Δerg5::ura4 arg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h+; The genotype of SD1832 is leu1-ade6-mat1Δ::hphSEVM caf5::bsdMX pap1Δpmd1Δmfs1Δbfr1Δdnf2Δerg5::ura4 arg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h+; The genotype of SD1833 is leu1-ade6-mat1Δ::hphSEVM caf5::bsdMX pap1Δpmd1Δmfs1Δbfr1Δdnf2Δerg5::ura4 arg6::PB[ura4]leu1-32::pDUAL-PBase(leu1+), and the mating type is h-.

3. Application of the highly sensitive drug screening platform based on the piggyBac transposition system according to any one of claims 1 or 2 in chemical small molecule drug screening.

4. Application of the highly sensitive drug screening platform based on the piggyBac transposition system according to any one of claims 1 or 2 in screening potential targets of the ferroptosis inducer Erastin and ferroptosis antagonism mechanism.

5. The use according to claim 4, characterized in that: The specific steps of the application are as follows: Step 1, obtain the appropriate PB-MDR strain and Erastin treatment concentration through a spot selection experiment, and then obtain the Erastin treatment time through a growth curve experiment; Step 2: construct a super-sensitive mutant library of PB insertion in the whole genome, and then use a spot selection experiment to obtain the super-sensitive mutant library of PB insertion treated with Erastin drug concentration and time, and then collect the bacteria and extract the genome; Step 3, constructing the super-sensitive mutant library of PB inserted after Erastin drug treatment in step 2 by Tn5 transposase method, and then performing high-throughput sequencing; Step 4: Perform bioinformatics analysis on the potential targets and cell antagonism mechanisms of Erastin.